GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GlaxoSmithKline PLC (LON:GSK) announced it has fired Moncef Slaoui as chair of Galvani Bioelectronics, a chronic disease research firm where it is the majority shareholder. Slaoui is the former head of the FTSE 100 firm's vaccines department and lead the US government's Operation Warp Speed, a project announced by Donald Trump to develop a COVID-19 jab, from May 2020 to January 2021.

GlaxoSmithKline dismisses former US vaccine executive from board of investee over sexual harassment allegations

Moncef Slaoui, former chief scientist of Operation Warp Speed during the Trump administration, was fired as Galvani Bioelectronics' board chairman over “substantiated” sexual harassment allegations by a woman. Galvani Bioelectronics is a medical research company focused on developing bioelectronic medicines for the treatment of chronic diseases.

GSK Fires Moncef Slaoui Over Sexual Harassment Charges

GlaxoSmithKline said it's terminated Moncef Slaoui, the former head of Operation Warp Speed, as chair of majority held Galvani Bioelectronics. Glaxo said the termination came after a letter alleged sexual harassment and inappropriate conduct towards an employee when Slaoui was at Glaxo.

Glaxo says it's terminated former Trump vaccine czar over harassment allegation

Glaxosmithkline said that Moncef Slaoui has been dismissed as chairman of Galvani Bioelectronics, which is majority owned by GSK.

GSK says Moncef Slaoui dismissed as Galvani chairman

DraftKings

Southwest Airlines

Netflix

Alexion Pharma

Burlington Stores

Inovio Pharmaceuticals

MongoDB

Snowflake

With the trading day about halfway over, the broad markets had pulled back slightly.

DraftKings, GlaxoSmithKline, Netflix, Southwest and More Tuesday Afternoon Analyst Calls

AbbVie

Chevron

Gilead Sciences

Exxon Mobil

According to the High Dividend Yield Stocks page, a Premium feature of GuruFocus, five stocks with a dividend yield of at least 4% and double-digit guru buys over the past few months are AbbVie Inc. (NYSE:ABBV), Gilead Sciences Inc. (NASDAQ:GILD), Exxon Mobil Corp. (NYSE:XOM), Chevron Corp. (NYSE:CVX) and GlaxoSmithKline PLC (NYSE:GSK).

5 High Dividend Yield Stocks Broadly Bought by Gurus

Glaxo (GSK) is developing an anti-IL-5 monoclonal antibody candidate, GSK3511294 - engineered for high affinity and long-acting suppression of IL-5 function - for treating severe asthma patients.

Glaxo (GSK) Begins Late-Stage Severe Eosinophilic Asthma Study

Privately-held Boston Pharmaceuticals has announced a three-year out-license and option agreement with GlaxoSmithKline Plc (NYSE: GSK) to advance pre-phase 2 programs. Initially, GSK will out-license and option two programs to Boston Pharmaceuticals: GSK3903371, a monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein, a tumor-associated antigen driving tumor growth and immunosuppression.

GSK Out-Licenses Two Drug Candidates To Boston Pharmaceuticals

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals announced today a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC (LSE/NYSE: GSK). Boston Pharmaceuticals will become a preferred GSK partner for select pre-phase 2 programs. This new agreement builds on the relationship established in 2018 with Boston Pharmaceuticals' acquisition of five GSK programs. “This new agreement validates Boston Pharmaceuticals as a trusted development partner with whom pharmaceu

Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs

Vectura Group PLC (LON:VEC) said it will pay a special dividend of £115mln during 2021 after receiving millions from GlaxoSmithKline PLC (LON:GSK) regarding a US patent litigation. The FTSE 250 pharma company has received £127.6mln, including payment for the settlement of damages, associated interest and royalties accrued up to the third quarter, and payment for fourth-quarter ongoing royalties.

Vectura =unveils special dividend after GlaxoSmithKline pays millions for litigation

GlaxoSmithKline PLC (LON:GSK) has started Phase 3 clinical testing of a plant-derived COVID-19 vaccine candidate developed by Canadian partner Medicago. Takashi Nagao, Medicago's chief executive, said: "This brings us one step closer to delivering an important new COVID-19 vaccine and contributing to the global fight against the pandemic along with our partner GSK.

GlaxoSmithKline starts fast-track coronavirus vaccine trial with Medicago

GlaxoSmithKline Plc (NYSE: GSK) hopes for better luck with its second partner Medicago, after tripping up in a recent COVID-19 vaccine test with Sanofi SA (NASDAQ: SNY).  GSK and Medicago will start Phase 3 testing of Medicago's COVID-19 vaccine candidate combined with GSK's pandemic adjuvant.

GSK Kick Starts Late-Stage Study With Medicago-Partnered COVID-19 Vaccine

QUEBEC CITY & LONDON--(BUSINESS WIRE)--Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate

Medicago and GSK Start Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate

Sanofi

Telesis Bio Inc

Moderna

The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.

Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage

Vir Biotechnology (VIR) and partner Glaxo's, antibody candidate, VIR-7831, reduces hospitalization and risk of death in early treatment of adult patients with COVID-19.

Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization Risk

Vir Biotechnology

GlaxoSmithKline and Vir Biotechnology said Wednesday their antibody drug reduced the risk of hospitalization and death in high-risk Covid-19 patients — and Vir stock catapulted Thursday. The post Vir Stock Catapults After Its GSK-Partnered Covid Drug Succeeds In New Test appeared first on Investor's Business Daily.

Vir Stock Catapults After Its GSK-Partnered Covid Drug Succeeds In New Test

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) has increased by over 50% pre-market. This is why it happened.

VIR Stock Price Increases Over 50% Pre-Market: Why It Happened

An Independent Data Monitoring Committee (IDMC) has recommended that the Phase 3 COMET-ICE trial, evaluating VIR-7831 (GSK4182136) as monotherapy for COVID-19, stop enrollment due to evidence of profound efficacy. The antibody treatment is being developed under a collaboration between Vir Biotechnology Inc's (NASDAQ: VIR) and GlaxoSmithKline Plc' (NYSE: GSK).

Vir/GSK's COVID-19 Antibody Therapy Cuts Hospitalization, Deaths by 85%, Seeks FDA Emergency Use Nod

GlaxoSmithKline PLC (LON:GSK) said an independent data monitoring committee (IDMC) recommended to stop the final phase of trials on a COVID-19 treatment because it's very effective. VIR-7831 is a monoclonal antibody developed in collaboration with Vir Biotechnology Inc (NASDAQ:VIR), after the pair agreed to work together on potential COVID-19 solutions last April.

GlaxoSmithKline recommended to stop COVID-19 treatment trials early because of high efficacy

– Independent Data Monitoring Committee recommends stopping Phase 3 COMET-ICE trial early given an 85% reduction in hospitalization or death –

Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19

GlaxoSmithKline plc (GSK) Presents at Barclays Global Healthcare Conference 2021 (Transcript)

The relationship could result in a marriage down the line.

After 2 Licensing Deals Will GlaxoSmithKline Acquire Vir?

The biotech's pipeline gets a seal of approval.

Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to Flu

Will Sanofi and GlaxoSmithKline Be Too Late to the Party With Their COVID Vaccine?

Emerging data cast doubt on the effectiveness of Vir Biotechnology and GlaxoSmithKline's Covid-19 treatment, leading Vir stock to plummet Wednesday. Shares fell more than 27%.

News for GlaxoSmithKline Stock (GSK)